Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Predispositional genome sequencing in healthy adults: design, participant characteristics, and early outcomes of the PeopleSeq Consortium.

Zoltick ES, Linderman MD, McGinniss MA, Ramos E, Ball MP, Church GM, Leonard DGB, Pereira S, McGuire AL, Caskey CT, Sanderson SC, Schadt EE, Nielsen DE, Crawford SD, Green RC; PeopleSeq Consortium.

Genome Med. 2019 Feb 27;11(1):10. doi: 10.1186/s13073-019-0619-9.

2.

Exploring Genetic Data Across Individuals: Design and Evaluation of a Novel Comparative Report Tool.

Westendorf L, Shaer O, Pollalis C, Verish C, Nov O, Ball MP.

J Med Internet Res. 2018 Sep 24;20(9):e10297. doi: 10.2196/10297.

3.

An unbiased index to quantify participant's phenotypic contribution to an open-access cohort.

Chan Y, Tung M, Garruss AS, Zaranek SW, Chan YK, Lunshof JE, Zaranek AW, Ball MP, Chou MF, Lim ET, Church GM.

Sci Rep. 2017 Apr 7;7:46148. doi: 10.1038/srep46148.

4.

The whole genome sequences and experimentally phased haplotypes of over 100 personal genomes.

Mao Q, Ciotlos S, Zhang RY, Ball MP, Chin R, Carnevali P, Barua N, Nguyen S, Agarwal MR, Clegg T, Connelly A, Vandewege W, Zaranek AW, Estep PW, Church GM, Drmanac R, Peters BA.

Gigascience. 2016 Oct 11;5(1):42.

5.

A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA.

Schizophr Res. 2015 May;164(1-3):136-42. doi: 10.1016/j.schres.2015.01.041. Epub 2015 Feb 24.

PMID:
25728831
6.

Harvard Personal Genome Project: lessons from participatory public research.

Ball MP, Bobe JR, Chou MF, Clegg T, Estep PW, Lunshof JE, Vandewege W, Zaranek A, Church GM.

Genome Med. 2014 Feb 28;6(2):10. doi: 10.1186/gm527.

7.

Our genomes today: time to be clear.

Lunshof JE, Ball MP.

Genome Med. 2013 Jun 27;5(6):52. doi: 10.1186/gm456. eCollection 2013. No abstract available.

8.

Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL.

J Clin Psychopharmacol. 2013 Feb;33(1):118-20. doi: 10.1097/JCP.0b013e3182793843. No abstract available. Erratum in: J Clin Psychopharmacol. 2016 Feb;36(1):26.

9.

A public resource facilitating clinical use of genomes.

Ball MP, Thakuria JV, Zaranek AW, Clegg T, Rosenbaum AM, Wu X, Angrist M, Bhak J, Bobe J, Callow MJ, Cano C, Chou MF, Chung WK, Douglas SM, Estep PW, Gore A, Hulick P, Labarga A, Lee JH, Lunshof JE, Kim BC, Kim JI, Li Z, Murray MF, Nilsen GB, Peters BA, Raman AM, Rienhoff HY, Robasky K, Wheeler MT, Vandewege W, Vorhaus DB, Yang JL, Yang L, Aach J, Ashley EA, Drmanac R, Kim SJ, Li JB, Peshkin L, Seidman CE, Seo JS, Zhang K, Rehm HL, Church GM.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11920-7. doi: 10.1073/pnas.1201904109. Epub 2012 Jul 13.

10.

Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells.

Peters BA, Kermani BG, Sparks AB, Alferov O, Hong P, Alexeev A, Jiang Y, Dahl F, Tang YT, Haas J, Robasky K, Zaranek AW, Lee JH, Ball MP, Peterson JE, Perazich H, Yeung G, Liu J, Chen L, Kennemer MI, Pothuraju K, Konvicka K, Tsoupko-Sitnikov M, Pant KP, Ebert JC, Nilsen GB, Baccash J, Halpern AL, Church GM, Drmanac R.

Nature. 2012 Jul 11;487(7406):190-5. doi: 10.1038/nature11236.

11.

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR.

Schizophr Res. 2012 Apr;136(1-3):25-31. doi: 10.1016/j.schres.2011.11.001. Epub 2011 Dec 12.

PMID:
22169248
12.

Phased whole-genome genetic risk in a family quartet using a major allele reference sequence.

Dewey FE, Chen R, Cordero SP, Ormond KE, Caleshu C, Karczewski KJ, Whirl-Carrillo M, Wheeler MT, Dudley JT, Byrnes JK, Cornejo OE, Knowles JW, Woon M, Sangkuhl K, Gong L, Thorn CF, Hebert JM, Capriotti E, David SP, Pavlovic A, West A, Thakuria JV, Ball MP, Zaranek AW, Rehm HL, Church GM, West JS, Bustamante CD, Snyder M, Altman RB, Klein TE, Butte AJ, Ashley EA.

PLoS Genet. 2011 Sep;7(9):e1002280. doi: 10.1371/journal.pgen.1002280. Epub 2011 Sep 15.

13.

Neuronal activity modifies the DNA methylation landscape in the adult brain.

Guo JU, Ma DK, Mo H, Ball MP, Jang MH, Bonaguidi MA, Balazer JA, Eaves HL, Xie B, Ford E, Zhang K, Ming GL, Gao Y, Song H.

Nat Neurosci. 2011 Aug 28;14(10):1345-51. doi: 10.1038/nn.2900.

14.

Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis.

Weiner E, Ball MP, Buchholz AS, Gold JM, Evins AE, McMahon RP, Buchanan RW.

J Clin Psychiatry. 2012 Jan;73(1):95-102. doi: 10.4088/JCP.10m06143gre. Epub 2011 Apr 5.

PMID:
21535998
15.

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.

Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW.

Clin Schizophr Relat Psychoses. 2011 Apr;5(1):17-25. doi: 10.3371/CSRP.5.1.3.

PMID:
21459735
16.

Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia.

Warren KR, Ball MP, Feldman S, Liu F, McMahon RP, Kelly DL.

Biol Res Nurs. 2011 Oct;13(4):383-90. doi: 10.1177/1099800410393272. Epub 2010 Dec 30.

17.

Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Wehring HJ, McMahon RP, Huestis MA, Heishman SJ, Warren KR, Buchanan RW.

J Clin Psychopharmacol. 2011 Feb;31(1):86-91. doi: 10.1097/JCP.0b013e318204825b.

18.

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.

Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR.

Biol Psychiatry. 2011 Mar 1;69(5):442-9. doi: 10.1016/j.biopsych.2010.09.052. Epub 2010 Dec 8.

19.

Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program.

Mann-Wrobel MC, Bennett ME, Weiner EE, Buchanan RW, Ball MP.

Schizophr Res. 2011 Mar;126(1-3):277-83. doi: 10.1016/j.schres.2010.10.030. Epub 2010 Nov 26.

PMID:
21112185
20.

Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.

Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW.

Neuropsychopharmacology. 2010 Oct;35(11):2274-83. doi: 10.1038/npp.2010.101. Epub 2010 Jul 21.

21.

A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.

Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, Gold JM, Ball MP, Feldman S, Liu F, Conley RR.

J Clin Psychiatry. 2009 Apr;70(4):518-25. Epub 2009 Apr 7.

PMID:
19358788
22.

Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells.

Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, Xie B, Daley GQ, Church GM.

Nat Biotechnol. 2009 Apr;27(4):361-8. doi: 10.1038/nbt.1533. Epub 2009 Mar 29. Erratum in: Nat Biotechnol. 2009 May;27(5):485.

23.

The effects of galantamine on psychopathology in chronic stable schizophrenia.

Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball MP, Buchanan RW.

Clin Neuropharmacol. 2009 Mar-Apr;32(2):69-74. doi: 10.1097/WNF.0B013E31816F2795.

24.

Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.

Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW.

J Psychopharmacol. 2009 Jun;23(4):436-41. doi: 10.1177/0269881108093883. Epub 2008 Jun 26.

25.

Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR.

Am J Psychiatry. 2008 Aug;165(8):1040-7. doi: 10.1176/appi.ajp.2008.07071135. Epub 2008 Apr 1.

26.

Galantamine for the treatment of cognitive impairments in people with schizophrenia.

Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP.

Am J Psychiatry. 2008 Jan;165(1):82-9. Epub 2007 Nov 6.

PMID:
17986678
27.

Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.

McKee JR, Bodfish JW, Mahorney SL, Heeth WL, Ball MP.

J Clin Psychiatry. 2005 Sep;66(9):1161-8.

PMID:
16187775
28.

Clozapine-induced hyperlipidemia resolved after switch to aripiprazole therapy.

Ball MP, Hooper ET, Skipwith DF, Cates ME.

Ann Pharmacother. 2005 Sep;39(9):1570-2. Epub 2005 Jul 26.

PMID:
16046490
29.

Olanzapine treatment of residual positive and negative symptoms.

Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold JM, McMahon RP, Carpenter WT Jr.

Am J Psychiatry. 2005 Jan;162(1):124-9.

PMID:
15625210
30.

A program for treating olanzapine-related weight gain.

Ball MP, Coons VB, Buchanan RW.

Psychiatr Serv. 2001 Jul;52(7):967-9.

PMID:
11433117
31.

Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia.

Weiner E, Ball MP, Summerfelt A, Gold J, Buchanan RW.

Am J Psychiatry. 2001 Apr;158(4):635-7.

PMID:
11282701

Supplemental Content

Support Center